Are there new drugs approved specifically for Myelodysplastic Syndromes anemia?
Yes, newer drugs like luspatercept, imetelstat, and lenalidomide are approved for anemia in lower-risk MDS, with more in development.
Read the full answer →Can Revlimid help with anemia in low-risk Myelodysplastic Syndromes?
Yes, Revlimid (lenalidomide) is FDA-approved for transfusion-dependent anemia in low- or intermediate-1-risk MDS with a deletion 5q abnormality.
Read the full answer →Is Rytelo approved for patients with transfusion-dependent anemia in Myelodysplastic Syndromes?
Yes, Rytelo (imetelstat) is FDA-approved for adults with low- to intermediate-1 risk MDS and transfusion-dependent anemia who need ≥4 RBC units over 8 weeks and have not responded to or are ineligible for ESAs.
Read the full answer →What genetic factors might increase Myelodysplastic Syndromes risk?
Genetic factors that may increase MDS risk include inherited variants near the API5 gene (OR=2.21) and acquired mutations in genes like TET2, ASXL1, DNMT3A, and SF3B1.
Read the full answer →Does the FDA approve Rytelo for low-risk Myelodysplastic Syndromes?
Yes, the FDA approved Rytelo (imetelstat) in June 2024 for adults with low- to intermediate-1 risk MDS who have transfusion-dependent anemia and have not responded to or are ineligible for ESAs.
Read the full answer →Can Revlimid be used to treat anemia in Myelodysplastic Syndromes?
Yes, Revlimid (lenalidomide) is FDA-approved for transfusion-dependent anemia in low- or intermediate-1-risk MDS with a deletion 5q abnormality.
Read the full answer →